(PRWEB) October 07, 2013
Patheon Inc., a leading provider of contract development and commercial manufacturing services to the global pharmaceutical industry, will showcase its offerings, including non-sterile, sterile and softgel dose forms at CPhI/ICSE in Messe Frankfurt, Germany, Oct. 22-24, 2013.
Patheon’s Harry Gill, senior vice president, quality and continuous improvement, will present “Utilizing Operational Excellence Principles to Drive Quality Improvements” on Wednesday, Oct. 23 at 2:30 p.m. CET in Hall 4.2 Booth L52. During the presentation, Gill will discuss how the company’s Patheon Advantage II program has been one of the main drivers of its efficiency improvement efforts. Patheon has utilized these same philosophies to create improvements in its quality performance, in particular Right First Time, which is a key performance indicator for both Patheon and its clients.
In addition, many Patheon executives, technical and scientific experts will also attend CPhI/ICSE and will be available to discuss Patheon’s non-sterile, sterile and softgel capabilities for development and commercial. Patheon’s experience encompasses thousands of projects for pharmaceutical and biotechnology companies of all types and sizes. The company gives access to the expertise, proven quality and global resources to bring drug candidates from preclinical stages through commercial production. Patheon will be exhibiting at Hall 4.2, Booth 42G03 for the duration of the conference. To schedule a meeting in advance, please email media(at)patheon(dot)com.
CPhI Worldwide 2013 is the world’s leading pharmaceutical networking event and is co-located with ICSE, P-MEC Europe & InnoPack. The unique event attracts more than 29,500 attendees from over 130 countries and 2,200 exhibitors.
For more information on upcoming events, visit http://www.patheon.com/Knowledge-Library/Events.aspx.
About Patheon Inc.
Patheon Inc. (TSX: PTI) is a leading provider of contract development and commercial manufacturing services to the global pharmaceutical industry for a full array of solid and sterile dosage forms. Through the company’s recent acquisition of Banner Pharmacaps – a market leader in soft gelatin capsule technology – Patheon now also includes a proprietary products and technology business.
Patheon provides the highest quality products and services to approximately 300 of the world’s leading pharmaceutical and biotechnology companies. The company’s integrated network consists of 16 locations, including 13 commercial contract manufacturing facilities and 9 product development centers across North America and Europe. Patheon enables customer products to be launched with confidence anywhere in the world. For more information, visit http://www.patheon.com.